Thymosin Alpha-1 (Tα1)
A thymic peptide studied internationally and in clinical research for immune modulation; no FDA-approved U.S. indication exists.
OVERVIEW
Thymosin Alpha-1 is a naturally occurring 28-amino-acid thymic peptide that modulates innate and adaptive immune activity. It has been studied internationally in immune-related conditions, but it is not FDA-approved in the United States.
Proposed Mechanisms
• Innate and adaptive immune modulation • T-cell and dendritic-cell signaling • Cytokine regulation
Potential Applications
• Immune-deficiency research • Chronic viral-infection research • Oncology adjunct research • Vaccine-response research • Sepsis and immune-dysregulation research
Pharmacokinetics
The source draft cited subcutaneous administration, peak concentration at about 1–2 hours, an approximately 2-hour terminal half-life, extracellular-fluid distribution, and proteolytic degradation.
Dosing
No FDA-approved U.S. dosing. The source draft noted that some international studies or approvals used 1.6 mg subcutaneously twice weekly; this must not be presented as a U.S. prescribing recommendation.
Monitoring
Disease- and protocol-specific. No general FDA-approved U.S. monitoring framework exists.
Side Effects
Not fully summarized in the source draft; compounded-product quality, immunogenicity, and patient-specific adverse effects require consideration.
Contraindications
No FDA-approved U.S. labeling or established U.S. contraindication profile.
FDA/Investigational Status
Not FDA-approved in the United States. FDA identifies inadequate safety information and potential immunogenicity and impurity concerns for compounded Thymosin Alpha-1.
Disclaimer/Notes
Educational resource only. Do not describe Thymosin Alpha-1 as similar to TB-500; they are distinct molecules with different research contexts.
Clinical Review Status
Clinical + legal review required before publishing